ALF-话题@MedSci

#ALF#

22篇内容 | 1595人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1941199, encodeId=359e1941199c0, content=<a href='/topic/show?id=3a862292cd' target=_blank style='color:#2F92EE;'>#ALF#</a>, objectTitle=Stroke ：凝血障碍导致的脑出血，andexanet alfa治疗并未改变临床预后, objectType=article, longId=218793, objectId=b0c4218e93f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b0c4218e93f9, replyNumber=0, likeNumber=78, createdTime=2022-01-24, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b0c4218e93f9, moduleTitle=Stroke ：凝血障碍导致的脑出血，andexanet alfa治疗并未改变临床预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b0c4218e93f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1941201, encodeId=234e194120182, content=<a href='/topic/show?id=3a862292cd' target=_blank style='color:#2F92EE;'>#ALF#</a>, objectTitle=NeuroImage：静息态fALFF和ReHo可表征代谢情况, objectType=article, longId=294552, objectId=834729455254, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=834729455254, replyNumber=0, likeNumber=80, createdTime=2022-11-17, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=834729455254, moduleTitle=NeuroImage：静息态fALFF和ReHo可表征代谢情况, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=834729455254)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1941200, encodeId=db0a1941200b8, content=<a href='/topic/show?id=3a862292cd' target=_blank style='color:#2F92EE;'>#ALF#</a>, objectTitle=Aimmune Therapeutics在EAACI PAAM数字会议上呈报长期每日口服免疫治疗药物PALFORZIA®（花生过敏原粉剂-dnfp）的免疫学结果新数据, objectType=article, longId=220575, objectId=ad652205e545, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad652205e545, replyNumber=0, likeNumber=72, createdTime=2022-07-04, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad652205e545, moduleTitle=Aimmune Therapeutics在EAACI PAAM数字会议上呈报长期每日口服免疫治疗药物PALFORZIA®（花生过敏原粉剂-dnfp）的免疫学结果新数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad652205e545)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1941198, encodeId=bfd11941198f2, content=<a href='/topic/show?id=3a862292cd' target=_blank style='color:#2F92EE;'>#ALF#</a>, objectTitle=Neurology：Andexanet Alfa在凝血因子Xa抑制剂相关性脑出血中的临床意义, objectType=article, longId=218655, objectId=6cb42186550a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6cb42186550a, replyNumber=0, likeNumber=84, createdTime=2022-03-07, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6cb42186550a, moduleTitle=Neurology：Andexanet Alfa在凝血因子Xa抑制剂相关性脑出血中的临床意义, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6cb42186550a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1941197, encodeId=c3fd194119efb, content=<a href='/topic/show?id=3a862292cd' target=_blank style='color:#2F92EE;'>#ALF#</a>, objectTitle=默克（Merck KGaA）的胆道癌疗法Bintrafusp Alfa，研究结果令人失望, objectType=article, longId=208490, objectId=f6302084901e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f6302084901e, replyNumber=0, likeNumber=86, createdTime=2022-02-09, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f6302084901e, moduleTitle=默克（Merck KGaA）的胆道癌疗法Bintrafusp Alfa，研究结果令人失望, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f6302084901e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1941196, encodeId=4252194119675, content=<a href='/topic/show?id=3a862292cd' target=_blank style='color:#2F92EE;'>#ALF#</a>, objectTitle=多灶性白质脑病如何治疗？NT-I7（efineptakin alfa）将进入临床试验阶段, objectType=article, longId=207572, objectId=421220e57265, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=421220e57265, replyNumber=0, likeNumber=0, createdTime=2021-07-09, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=421220e57265, moduleTitle=多灶性白质脑病如何治疗？NT-I7（efineptakin alfa）将进入临床试验阶段, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=421220e57265)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1941195, encodeId=7851194119515, content=<a href='/topic/show?id=3a862292cd' target=_blank style='color:#2F92EE;'>#ALF#</a>, objectTitle=A型血友病，Efanesoctocog alfa被FDA授予“快速通道资格”, objectType=article, longId=207423, objectId=044820e4234d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=044820e4234d, replyNumber=0, likeNumber=0, createdTime=2022-01-13, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=044820e4234d, moduleTitle=A型血友病，Efanesoctocog alfa被FDA授予“快速通道资格”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=044820e4234d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1941194, encodeId=3d671941194ac, content=<a href='/topic/show?id=3a862292cd' target=_blank style='color:#2F92EE;'>#ALF#</a>, objectTitle=FDA延长法布雷病治疗药物长效α-半乳糖苷酶A产品pegunigalsidase alfa审查周期, objectType=article, longId=204053, objectId=0bbe204053d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0bbe204053d5, replyNumber=0, likeNumber=97, createdTime=2020-12-12, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0bbe204053d5, moduleTitle=FDA延长法布雷病治疗药物长效α-半乳糖苷酶A产品pegunigalsidase alfa审查周期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0bbe204053d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1941193, encodeId=11881941193cf, content=<a href='/topic/show?id=3a862292cd' target=_blank style='color:#2F92EE;'>#ALF#</a>, objectTitle=Blood：重组FVIII药物Rurioctocog alfa pegol预防性治疗A型血友病, objectType=article, longId=203528, objectId=9b0d20352851, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9b0d20352851, replyNumber=0, likeNumber=83, createdTime=2021-08-03, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9b0d20352851, moduleTitle=Blood：重组FVIII药物Rurioctocog alfa pegol预防性治疗A型血友病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9b0d20352851)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1941190, encodeId=6534194119000, content=<a href='/topic/show?id=3a862292cd' target=_blank style='color:#2F92EE;'>#ALF#</a>, objectTitle=Aimmune的Palforzia成为美国批准的**种花生过敏治疗药物, objectType=article, longId=187153, objectId=ed5018e153aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed5018e153aa, replyNumber=0, likeNumber=0, createdTime=2020-09-05, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed5018e153aa, moduleTitle=Aimmune的Palforzia成为美国批准的**种花生过敏治疗药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ed5018e153aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1941192, encodeId=0d37194119238, content=<a href='/topic/show?id=3a862292cd' target=_blank style='color:#2F92EE;'>#ALF#</a>, objectTitle=新型合成干扰素Alfacyte™治疗COVID-19：已取得重大突破, objectType=article, longId=201834, objectId=0fef201834ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0fef201834ee, replyNumber=0, likeNumber=105, createdTime=2021-01-31, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0fef201834ee, moduleTitle=新型合成干扰素Alfacyte™治疗COVID-19：已取得重大突破, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0fef201834ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1941191, encodeId=b5e81941191a8, content=<a href='/topic/show?id=3a862292cd' target=_blank style='color:#2F92EE;'>#ALF#</a>, objectTitle=Lancet haematol：Ropeginterferon alfa-2b对比羟基脲用于真性红细胞增多症的长期疗效！, objectType=article, longId=187425, objectId=b82918e4252e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b82918e4252e, replyNumber=0, likeNumber=71, createdTime=2020-12-30, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b82918e4252e, moduleTitle=Lancet haematol：Ropeginterferon alfa-2b对比羟基脲用于真性红细胞增多症的长期疗效！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b82918e4252e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1941189, encodeId=2067194118975, content=<a href='/topic/show?id=3a862292cd' target=_blank style='color:#2F92EE;'>#ALF#</a>, objectTitle=FDA支持Aimmune的花生过敏疗法Palforzia, objectType=article, longId=179447, objectId=8a871e9447d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8a871e9447d1, replyNumber=0, likeNumber=0, createdTime=2019-10-16, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8a871e9447d1, moduleTitle=FDA支持Aimmune的花生过敏疗法Palforzia, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8a871e9447d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1941186, encodeId=1ea6194118629, content=<a href='/topic/show?id=3a862292cd' target=_blank style='color:#2F92EE;'>#ALF#</a>, objectTitle=他汀类药物幕后的无名英雄Alfred Alberts逝世, objectType=article, longId=142806, objectId=92dd142806ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=92dd142806ec, replyNumber=0, likeNumber=78, createdTime=2018-11-20, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=92dd142806ec, moduleTitle=他汀类药物幕后的无名英雄Alfred Alberts逝世, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=92dd142806ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1941187, encodeId=555e194118ec0, content=<a href='/topic/show?id=3a862292cd' target=_blank style='color:#2F92EE;'>#ALF#</a>, objectTitle=Hum Genome Var：原因不明的发热引起的ALF复发或肝功能不全的儿童进行NBAS基因分析的结果, objectType=article, longId=157989, objectId=802315e98972, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=802315e98972, replyNumber=0, likeNumber=81, createdTime=2019-12-08, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=802315e98972, moduleTitle=Hum Genome Var：原因不明的发热引起的ALF复发或肝功能不全的儿童进行NBAS基因分析的结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=802315e98972)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1941188, encodeId=3c29194118828, content=<a href='/topic/show?id=3a862292cd' target=_blank style='color:#2F92EE;'>#ALF#</a>, objectTitle=第15届年度WORLDSymposium：pegunigalsidase alfa用于治疗法布里病的初步数据, objectType=article, longId=159195, objectId=33e315919506, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=33e315919506, replyNumber=0, likeNumber=81, createdTime=2019-05-30, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=33e315919506, moduleTitle=第15届年度WORLDSymposium：pegunigalsidase alfa用于治疗法布里病的初步数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=33e315919506)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1941184, encodeId=d3a11941184bd, content=<a href='/topic/show?id=3a862292cd' target=_blank style='color:#2F92EE;'>#ALF#</a>, objectTitle=NEJM：sebelipase alfa治疗溶酶体酸性脂肪酶缺乏症效果良好, objectType=article, longId=56057, objectId=feed5605e5b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=feed5605e5b, replyNumber=0, likeNumber=75, createdTime=2015-11-26, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=feed5605e5b, moduleTitle=NEJM：sebelipase alfa治疗溶酶体酸性脂肪酶缺乏症效果良好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=feed5605e5b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1941183, encodeId=1d5b194118366, content=<a href='/topic/show?id=3a862292cd' target=_blank style='color:#2F92EE;'>#ALF#</a>, objectTitle=招募患者：未接受过治疗的儿童血友病A患者中应用turoctocog alfa预防和治疗出血的安全性和有效性临床试验, objectType=article, longId=56020, objectId=e4b556020a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e4b556020a4, replyNumber=0, likeNumber=90, createdTime=2016-01-27, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4b556020a4, moduleTitle=招募患者：未接受过治疗的儿童血友病A患者中应用turoctocog alfa预防和治疗出血的安全性和有效性临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e4b556020a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1941185, encodeId=534c1941185cd, content=<a href='/topic/show?id=3a862292cd' target=_blank style='color:#2F92EE;'>#ALF#</a>, objectTitle=NEJM：Andexanet Alfa可逆转Xa因子抑制剂的活性, objectType=article, longId=60767, objectId=65ff60e67cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=65ff60e67cf, replyNumber=0, likeNumber=71, createdTime=2016-07-14, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=65ff60e67cf, moduleTitle=NEJM：Andexanet Alfa可逆转Xa因子抑制剂的活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=65ff60e67cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1941182, encodeId=b0871941182ca, content=<a href='/topic/show?id=3a862292cd' target=_blank style='color:#2F92EE;'>#ALF#</a>, objectTitle=纪念伟大的免疫学家：Donald Metcalf, objectType=article, longId=46437, objectId=7d3f4643eef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7d3f4643eef, replyNumber=0, likeNumber=72, createdTime=2015-10-05, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7d3f4643eef, moduleTitle=纪念伟大的免疫学家：Donald Metcalf, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7d3f4643eef)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

ALF

2020-05-29

xiongliangxl (审核中...)

前往app查看评论内容

#ALF#

Stroke ：凝血障碍导致的脑出血，andexanet alfa治疗并未改变临床预后

2022-01-24

xiongliangxl (审核中...)

前往app查看评论内容

#ALF#

NeuroImage：静息态fALFF和ReHo可表征代谢情况

2022-11-17

xiongliangxl (审核中...)

前往app查看评论内容

#ALF#

Aimmune Therapeutics在EAACI PAAM数字会议上呈报长期每日口服免疫治疗药物PALFORZIA®（花生过敏原粉剂-dnfp）的免疫学结果新数据

2022-07-04

xiongliangxl (审核中...)

前往app查看评论内容

#ALF#

Neurology：Andexanet Alfa在凝血因子Xa抑制剂相关性脑出血中的临床意义

2022-03-07

xiongliangxl (审核中...)

前往app查看评论内容

#ALF#

默克（Merck KGaA）的胆道癌疗法Bintrafusp Alfa，研究结果令人失望

2022-02-09

xiongliangxl (审核中...)

前往app查看评论内容

#ALF#

多灶性白质脑病如何治疗？NT-I7（efineptakin alfa）将进入临床试验阶段

2021-07-09

xiongliangxl (审核中...)

前往app查看评论内容

#ALF#

A型血友病，Efanesoctocog alfa被FDA授予“快速通道资格”

2022-01-13

xiongliangxl (审核中...)

前往app查看评论内容

#ALF#

FDA延长法布雷病治疗药物长效α-半乳糖苷酶A产品pegunigalsidase alfa审查周期

2020-12-12

xiongliangxl (审核中...)

前往app查看评论内容

#ALF#

Blood：重组FVIII药物Rurioctocog alfa pegol预防性治疗A型血友病

2021-08-03

xiongliangxl (审核中...)

前往app查看评论内容

#ALF#

Aimmune的Palforzia成为美国批准的**种花生过敏治疗药物

2020-09-05

xiongliangxl (审核中...)

前往app查看评论内容

#ALF#

新型合成干扰素Alfacyte™治疗COVID-19：已取得重大突破

2021-01-31

xiongliangxl (审核中...)

前往app查看评论内容

#ALF#

Lancet haematol：Ropeginterferon alfa-2b对比羟基脲用于真性红细胞增多症的长期疗效！

2020-12-30

xiongliangxl (审核中...)

前往app查看评论内容

#ALF#

FDA支持Aimmune的花生过敏疗法Palforzia

2019-10-16

xiongliangxl (审核中...)

前往app查看评论内容

#ALF#

他汀类药物幕后的无名英雄Alfred Alberts逝世

2018-11-20

xiongliangxl (审核中...)

前往app查看评论内容

#ALF#

Hum Genome Var：原因不明的发热引起的ALF复发或肝功能不全的儿童进行NBAS基因分析的结果

2019-12-08

xiongliangxl (审核中...)

前往app查看评论内容

#ALF#

第15届年度WORLDSymposium：pegunigalsidase alfa用于治疗法布里病的初步数据

2019-05-30

xiongliangxl (审核中...)

前往app查看评论内容

#ALF#

NEJM：sebelipase alfa治疗溶酶体酸性脂肪酶缺乏症效果良好

2015-11-26

xiongliangxl (审核中...)

前往app查看评论内容

#ALF#

招募患者：未接受过治疗的儿童血友病A患者中应用turoctocog alfa预防和治疗出血的安全性和有效性临床试验

2016-01-27

xiongliangxl (审核中...)

前往app查看评论内容

#ALF#

NEJM：Andexanet Alfa可逆转Xa因子抑制剂的活性

2016-07-14

xiongliangxl (审核中...)

前往app查看评论内容

#ALF#

纪念伟大的免疫学家：Donald Metcalf

2015-10-05

科室
- - 订阅+
  - 更多科室
工具
服务